Overview

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

Status:
Recruiting

Trial end date:
2026-12-05

Target enrollment:

Participant gender:

Summary

The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and clinical activity of the R2PD of imetelstat in combination with ruxolitinib in participants with MF in Part 2.

Phase:

Phase 1

Details

Lead Sponsor:

Geron Corporation

Treatments:

Imetelstat
Motesanib diphosphate